Allarity Therapeutics, Inc. (ALLR)
(Delayed Data from NSDQ)
$0.17 USD
-0.02 (-9.92%)
Updated Jul 19, 2024 04:00 PM ET
Pre-Market: $0.17 0.00 (1.19%) 9:24 AM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALLR 0.17 -0.02(-9.92%)
Will ALLR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALLR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALLR
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
ALLR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ALLR
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
Allarity provides 2024 corporate update
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Allarity Therapeutics Secures Critical Nasdaq Hearing Opportunity
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance